Aptose Biosciences Inc. total revenue, net income and dynamics of changes in Euro today
Aptose Biosciences Inc. revenue for the past few reporting periods. Aptose Biosciences Inc. net revenue for today is 0 €. Net income of Aptose Biosciences Inc. today amounted to -13 470 000 €. The financial graph of Aptose Biosciences Inc. displays the online status: net income, net revenue, total assets. The financial report schedule from 31/03/2019 to 30/06/2021 is available online. The value of the "total revenue of Aptose Biosciences Inc." on the chart is marked in yellow.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
30/06/2021
0 €
-
-12 512 013.60 €
-
31/03/2021
0 €
-
-15 072 935.76 €
-
31/12/2020
0 €
-
-13 666 611.44 €
-
30/09/2020
0 €
-
-12 306 731.12 €
-
31/12/2019
0 €
-
-7 160 735.92 €
-
30/09/2019
0 €
-
-6 357 254.72 €
-
30/06/2019
0 €
-
-5 775 775.84 €
-
31/03/2019
0 €
-
-5 114 413.28 €
-
Show:
to
Aptose Biosciences Inc. financial report charts
The latest dates of Aptose Biosciences Inc. financial statements available online: 31/03/2019, 31/03/2021, 30/06/2021. The dates of financial statements are strictly regulated by law and financial statements. The latest financial report of Aptose Biosciences Inc. is available online for such a date - 30/06/2021. Operating income Aptose Biosciences Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Aptose Biosciences Inc. is -13 488 000 €
Aptose Biosciences Inc. quarterly report dates
Net income Aptose Biosciences Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Aptose Biosciences Inc. is -13 470 000 € Current assets Aptose Biosciences Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Aptose Biosciences Inc. is 105 305 000 € Total assets Aptose Biosciences Inc. refers to the total amount of assets owned by a person or entity. Total assets Aptose Biosciences Inc. is 106 211 000 €
Current cash Aptose Biosciences Inc. - the sum of all of the cash a company has on the date of report. Current cash Aptose Biosciences Inc. is 83 343 000 €
30/06/2021
31/03/2021
31/12/2020
30/09/2020
31/12/2019
30/09/2019
30/06/2019
31/03/2019
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
-
-
-
-
-
-
-
-
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
-
-
-
-
-
-
-
-
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
-
-
-
-
-
-
-
-
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
-
-
-
-
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-12 528 733.44 €
-15 096 157.76 €
-13 709 339.92 €
-12 348 530.72 €
-7 323 289.92 €
-6 527 239.76 €
-5 894 672.48 €
-5 201 728 €
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-12 512 013.60 €
-15 072 935.76 €
-13 666 611.44 €
-12 306 731.12 €
-7 160 735.92 €
-6 357 254.72 €
-5 775 775.84 €
-5 114 413.28 €
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
9 131 819.28 €
7 642 824.64 €
8 331 124.72 €
6 984 248.72 €
4 879 406.64 €
4 413 108.88 €
3 242 720.08 €
3 102 459.20 €
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
12 528 733.44 €
15 096 157.76 €
13 709 339.92 €
12 348 530.72 €
7 323 289.92 €
6 527 239.76 €
5 894 672.48 €
5 201 728 €
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
97 815 708.40 €
106 026 078.72 €
116 180 594.88 €
124 418 831.60 €
91 741 762.08 €
28 431 159.04 €
33 685 833.20 €
16 407 736.32 €
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
98 657 273.68 €
107 002 331.60 €
117 282 246.56 €
125 638 451.04 €
93 330 146.88 €
30 151 444.80 €
35 473 927.20 €
18 320 300.24 €
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
77 415 645.84 €
80 889 657.04 €
109 044 009.84 €
92 634 415.76 €
74 163 636.96 €
19 214 811.68 €
24 985 014.24 €
15 401 759.28 €
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
5 145 066.32 €
3 630 063.04 €
2 990 064.72 €
2 765 275.76 €
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
6 084 164 €
4 674 124.16 €
4 118 653.92 €
3 993 255.12 €
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
6.52 %
15.50 %
11.61 %
21.80 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
91 202 082.80 €
101 625 045.28 €
110 457 765.20 €
119 970 425.28 €
87 245 982.88 €
25 477 320.64 €
31 355 273.28 €
14 327 045.12 €
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
-5 787 851.28 €
-4 815 313.92 €
-4 894 268.72 €
-4 527 361.12 €
Last revenue report of Aptose Biosciences Inc. was 30/06/2021. According to last financial report total revenue in Aptose Biosciences Inc. was 0 Euro and changed by 0% since last year. Net income in Aptose Biosciences Inc. was -12 512 013.60 € in last quartal, net income changes to 0%.
Aptose Biosciences Inc. stocks data
LTIA.F stock price
Aptose Biosciences Inc. stock price today, LTIA.F stock quote.
